Agios narrows quarterly loss to $65 million as AQVESME sales climb

what happened

Biotech company Agios Pharmaceuticals released its third-quarter 2026 results. Its net loss came in at $65.0 million, down from $103.4 million a year earlier. According to GlobeNewswire, management described quarterly product sales as a record, but the press release did not give a specific revenue number.

TradingView, drawing on the company's SEC filing, reports that product revenue rose to $55.4 million from $12.9 million. U.S. sales reached $48.7 million, while revenue outside the country totaled $6.6 million. The operating loss narrowed to $77.2 million from $116.9 million, and cash, equivalents and marketable securities stood at $907.0 million as of September 30, 2026.

The company reaffirmed its aim of reaching non-GAAP profitability in 2028. The FDA pushed back its decision on mitapivat for sickle cell disease to February 1, 2027. Agios also plans to cut more than 100 research and development roles.

why it matters

Two points matter most for the market: the growing U.S. demand for AQVESME and the new FDA decision date. A smaller loss alongside rising revenue usually eases pressure on shares of companies like this, although the 2028 profit goal still looks distant. Investors will watch the mitapivat decision, which could open a new treatment market.

market impact

Agios shares: revenue growth and a smaller loss support the stock

• ▲Agios shares (AGIO) pressure up — revenue rose while the net loss narrowed sharply

tags

instruments

on polymarket